Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 114

Results For "disease"

2672 News Found

FDA approves Merck’s WINREVAIR for treatment of pulmonary arterial hypertension
Drug Approval | March 27, 2024

FDA approves Merck’s WINREVAIR for treatment of pulmonary arterial hypertension

WINREVAIR is a breakthrough biologic for this rare, progressive disease


Sanofi and Cipla enters into distribution partnership to expand reach of CNS portfolio in India
Supply Chain | March 27, 2024

Sanofi and Cipla enters into distribution partnership to expand reach of CNS portfolio in India

Cipla will be responsible for the distribution of Sanofi India's six CNS brands including Frisium


Ultomiris approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder
Drug Approval | March 27, 2024

Ultomiris approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder

First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+


AstraZeneca’s FLAURA2 Phase III trial showed favourable trend in EGFR-mutated advanced lung cancer
Clinical Trials | March 23, 2024

AstraZeneca’s FLAURA2 Phase III trial showed favourable trend in EGFR-mutated advanced lung cancer

Combination shows consistent benefit across prespecified post-progression outcomes


'Illness To Wellness’ joins hands with ILBS to generate awareness against Hepatitis B patients
News | March 23, 2024

'Illness To Wellness’ joins hands with ILBS to generate awareness against Hepatitis B patients

Hepatitis B infects over 40 million people in India


USFDA grants ODD to Cevidoplenib for immune thrombocytopenia
News | March 23, 2024

USFDA grants ODD to Cevidoplenib for immune thrombocytopenia

Oscotec has successfully completed phase 2 study in patients with chronic ITP last year


Zydus receives tentative approval from USFDA for Letermovir Tablets
Drug Approval | March 23, 2024

Zydus receives tentative approval from USFDA for Letermovir Tablets

Letermovir tablets, 240 mg and 480 mg had annual sales of USD 289.5 mn in the United States (IQVIA MAT Jan-24)


Bristol Myers Squibb completes acquisition of Karuna Therapeutics
News | March 21, 2024

Bristol Myers Squibb completes acquisition of Karuna Therapeutics

KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia


Dr. Reddy's Laboratories launches Versavo in the UK
News | March 19, 2024

Dr. Reddy's Laboratories launches Versavo in the UK

Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK